BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell 2022;185:2789-805. [PMID: 35868279 DOI: 10.1016/j.cell.2022.05.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu L, Chen J. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Medical Review 2023;0. [DOI: 10.1515/mr-2022-0033] [Reference Citation Analysis]
2 Svilenov HL, Arosio P, Menzen T, Tessier P, Sormanni P. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. MAbs 2023;15:2164459. [PMID: 36629855 DOI: 10.1080/19420862.2022.2164459] [Reference Citation Analysis]
3 Kobayashi H, Asano T, Suzuki H, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y. Establishment of a Sensitive Monoclonal Antibody Against Mouse CCR9 (C9Mab-24) for Flow Cytometry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2022. [DOI: 10.1089/mab.2022.0032] [Reference Citation Analysis]
4 Zhong X, D'Antona AM. A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production. Front Immunol 2022;13:1072702. [PMID: 36569848 DOI: 10.3389/fimmu.2022.1072702] [Reference Citation Analysis]
5 Pringle TA, Coleman O, Kawamura A, Knight JC. The influence of degree of labelling upon cellular internalisation of antibody-cell penetrating peptide conjugates. RSC Adv 2022;12:27716-22. [DOI: 10.1039/d2ra05274a] [Reference Citation Analysis]